tobrex opthalmic solution
novartis south africa (pty) ltd - tobramycin - opthalmic solution - tobramycin 3 mg/ml
tobrex opth.oint. 0.3% eye ointment
novartis pharma ag, switzerland - tobramycin - eye ointment - 0.3 %
tobradex ophthalmic suspension
novartis corporation (malaysia) sdn. bhd. - dexamethasone; tobramycin -
retaane
anecortave acetate -
tobradex ophthalmic ointment
novartis (singapore) pte ltd - dexamethasone; tobramycin - ointment - 0.10% - dexamethasone 0.1%; tobramycin 0.3%
tobramycin and dexamethasone suspension
h.j. harkins company, inc. - tobramycin (unii: vz8rrz51vk) (tobramycin - unii:vz8rrz51vk), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - tobramycin 3 mg in 1 ml - tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye